Gene silencing therapy’s fast-track approval to expand treatment options for Huntington’s patients
Globally, there are currently 24 products in clinical development for the treatment of...
Trending menu:
-
![eTMF Cancer Research]()
Exploring efficiencies from eTMF with Cancer Research UK
-
![Opdivo]()
Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma
-
![]()
Nerlynx (neratinib) for the Treatment of Breast Cancer
-
![]()
Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
-
![]()
Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma
-
![]()
Keytruda (pembrolizumab) for the Treatment of Metastatic Melanoma
Most Read
- Exploring efficiencies from eTMF with Cancer Research UK
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- New drugs and therapeutic options help the immune system fight cancer
- Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
- The challenges of using stem cells in neurology
Company A-Z
Latest Content
US-Australia led research reveals promising drug for blood cancer
An international research collaboration between the US and Australia has revealed a new drug for the treatment of patients affected with high-risk leukemia.
2020 Forthcoming Events
Below are the forthcoming shows that will exhibit Malvern’s pharmaceutical solutions.
Iovance and Cellectis agree research and license collaboration
US-based T cell-based cancer immunotherapies developer Iovance Biotherapeutics and clinical-stage biopharmaceutical firm Cellectis have signed a research collaboration and exclusive worldwide license agreement.
Nektar and Bristol-Myers Squibb expand clinical development programme
Nektar Therapeutics and Bristol-Myers Squibb Company have entered a revised strategic collaboration agreement to expand the clinical development programme for bempegaldesleukin (bempeg) plus Opdivo (nivolumab).
Veeva launches Vault Payments application to clinical research sites
Veeva Systems, a provider of Cloud-based software for the life sciences industry, has announced the launch of Veeva Vault Payments, a new add-on application for Veeva Vault CTMS.
Gene silencing therapy’s fast-track approval to expand treatment options for Huntington’s patients
Globally, there are currently 24 products in clinical development for the treatment of Huntington’s disease, which is a rare, inheritable neurodegenerative condition. Symptoms are typically noticed between the ages of 30 and 50 and include memory loss, anxiety, depression, and compulsive behaviors.
ClinOne to open first European office in UK
Clinical trial technologies and software supplier ClinOne is set to open its first European office in west London, UK.
AtreMorine: A Biotechnological / Nutraceutical product for Parkinson’s
AtreMorine is a novel biopharmaceutical compound obtained by means of nondenaturing biotechnological procedures from the structural components of the Vicia faba L plant, for the prevention and treatment of Parkinson´s disease (PD) and related disorders.
Alzheimer’s Disease Prevention Plan
Dr Ramón Cacabelos, Professor and Chairman of Genomic Medicine, announces the implementation of a Preventive Program for Alzheimer’s disease at the International Center of Neurosciences and Genomic Medicine, Corunna, Spain.
DHR Health Institute and TriNetX join global clinical research network
DHR Health Institute for Research and Development has formed a strategic partnership with global health network TriNetX.
Latest News
Close
Close
Close
Go Top
